hra ncats final slides 090412 research alliance members’meeting hosted by the foundation for the...
TRANSCRIPT
HEALTH RESEARCH ALLIANCEMEMBERS’ MEETING
Hosted by The Foundation for the National Institutes of Health
Hyatt Regency Bethesda | Bethesda, MarylandSeptember 6-7, 2012
A Case Study on a Ground-Breaking Public-Private Partnership:
NIH/NCATS and Eli Lilly & Company
G. Sitta Sittampalam, PhD (NCATS)Timothy Grese, PhD (Eli Lilly &Co)
Out line
National Center for Advancing Translational Sciences- Goals &Rationale for NCATS (NIH) – Lilly Collaboration- NCATS Mission- NCATS Pharmaceutical Collection (NPC)- A Case Study- The Learning Collaborative (TLC)
Eli Lilly & Co. – Open Innovation Drug Discovery- Establishment & Mission- Phenotypic Drug Discovery (PD2) - Target Drug Discovery Initiative (TargetD2)- Disease pathways of mutual interest.
- Pilot experiment to leverage assets/resources in public-private partnerships- Leverage Lilly Phenotypic Assay Panels – successful in OIDD- Benefits larger drug discovery community- Publish data jointly- build a “collaboration culture”- Collaboration culture = Competencies + Excellence in Science + Trust- Benefit TRND via repurposing NPC compounds
5,000 Years
Lilly-NCATS Collaboration- Goals & Rationale
Accomplishing this effort, even in a few years, makes a lot of sense!
• Screen NPC Collection in Lilly Phenotypic Assay Panels• Jointly publish data –availability to the broader scientific community• Understanding Systems Pharmacology of known drugs• Leverage data for The Rare & Neglected Diseases (TRND) programs
NCATSEstablished: December 23, 2011
Part of consolidated Appropriations Act 2012 (PL112-74)
NCATS Mission“To catalyze the generation of innovative methods and technologies that will enhance the development, testing, and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions
Current Organization
CAN- Cures Acceleration NetworkORDR-Office of Rare Diseases ResearchDPI- Division of Preclinical InnovationDCI- Division of Clinical Innovation
Clinical Translational Science AwardCTSA (Extramural)
NPC Screens at NCGC/NCATS
• NPC Collection has been screened in over 200 assay formats
• Assays represent ~ 25 different disease pathologies
• Examples: - Chronic Lymphocytic Leukemia (CLL)- Acute Myeloid Leukemia (AML) - Niemann-Pick Disease- Type C (NPC)- Transmissible spongiform encephalopathies (TSEs, Prion Disease)- Malaria, Giardia (Neglected Diseases)- Cryptococcal Meningitis
• All projects involves external collaborations with academic/non-profit partners
Chronic Lymphocytic Leukemia
102 molecules: CLL Pan actives vs. Normal B-cells
Doug Auld PhD., Adrien Wiestner MD. et al
From screen completion to clinic in ~17 months!A Rationale for starting the Lilly-NCATS collaboration
Current status - Lilly-NCATS Collaboration
• Publication of NPC collection (Sci. Transl. Med): April 2011
• NCATS- Lilly discussions: June - July 2011
• Collaborative Research Agreement signed: December 2011
• Press release : “NIH and Lilly to generate public resource of approved and investigational medicines” – March 13, 2012
• NCATS- Lilly Scientific and Steering Committees identified – April 2012.
• Compound acquisition and distribution – April-May 2012
• Phenotypic screens initiated at Lilly: July-August 2012
Initial discussions to initiating screens: ~ 12 months.
Lilly Open Innovation Drug Discovery Program
Timothy Grese, PhD.Chief Scientific Officer—Lead Generation and External Innovation
Discovery Chemistry Research and TechnologiesLilly Research Laboratories
Supplementary slides